Super-fast-acting prandial insulin product receives £0.5m Innovate UK boost
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that it has been awarded a £0.5m grant from Innovate UK to advance its proprietary super-fast-acting prandial insulin product, AT270.
Arecor featured by the highly regarded industry publication, Scrip
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available for viewing.
Arecor participates in PepTalk 2019’s Protein Science week in San Diego, CA, USA
Arecor Limited is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the largest annual gatherings of over 1,300 protein science researchers in the world, will be held between January 14-18, 2019, at the Hilton Hotel, San Diego Bayfront, San Diego, California, USA.
Arecor announces clinical trials application for ultra-rapid acting insulin product
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that the Company has filed a Clinical Trial Application (CTA) to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin product, AT247.
Arecor attends the 37TH annual JP Morgan Healthcare Conference
Arecor Ltd, the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, will be attending the 37th Annual JP Morgan Healthcare Conference in San Francisco, California, next month.
Arecor successfully defends a key European Patent
Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage.
Arecor secures £6m investment for clinical development of its diabetes portfolio
Arecor Ltd, the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.
Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018
Arecor Ltd, the UK-based leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.
Arecor successfully defends a key European polysaccharide vaccine patent
Arecor Ltd, the UK-based leading formulation technology company focused on developing superior biopharmaceuticals and vaccines via its innovative formulation technology, is pleased to announce the successful outcome to its opposition proceedings at the European Patent Office in relation to a key patent of the company’s broad portfolio.
Arecor announces superfast insulin data presentations at ADA scientific sessions
Arecor Ltd , the UK-based leading formulation technology company, today announces that its abstract supporting the application of its proprietary Arestat™ technology platform to enable a superfast insulin product has been accepted for a poster presentation at the upcoming American Diabetes Association (ADA) 78th Scientific Sessions, from June 22 - 26, 2018 in Orlando, FL, USA.
Arecor secures grant to advance co-formulation of critical pharmaceutical products
Innovate UK grant of nearly £1 million will be used to significantly advance Arecor’s proprietary co-formulation platform in the development of diabetes therapies that meet critical patient unmet needs.
Arecor at World Congress’ Biologics Formulation and Drug Delivery Technologies Summit
Arecor Limited, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions, is pleased to announce its participation at The World Congress’ Biologics Formulation and Drug Delivery Technologies Summit, on 21st and 22nd May 2018, at…
Arecor launches new website
Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce the launch of its new website.
European patent on the horizon for Arecor’s proprietary technology
Arecor Ltd is pleased to announce the European Patent Office (EPO) has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies such as trastuzumab or ustekinumab or fusion proteins such as abatacept…
Arecor and JDRF announce successful pre-clinical development of diabetes treatment
Arecor and JDRF announce the successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes.
Arecor’s vaccine stabilising formulation technology helps combat livestock diseases
Arecor Ltd, a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, ArestatTM, is pleased to announce that the Company, in partnership with GALVmed, has successfully applied its vaccine formulation technology to stabilise liquid formulations of vaccines to combat two major diseases of livestock in the developing world.
Arecor strengthens the patent portfolio of its formulation technology
Notification of an ‘intention to grant’ a patent protecting Arecor’s novel approach to enabling stable liquid adenovirus formulations has been received from both the European and US patent offices.
Arecor has been selected to appear in the 2016/2017 edition of The Parliamentary Review
“The Company features alongside The Prime Minister, The Rt Hon Theresa May MP, and a small number of outstanding organisations in the Technology edition”
Arecor announces license agreement with global pharmaceutical company
Arecor Ltd (“the Company”), the leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce that a global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to…
Arecor announces the inaugural formation of a global diabetes Scientific Advisory Board
Arecor Ltd, the leading formulation technology company, focused on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, announces the inaugural formation of a Global Diabetes Scientific Advisory Board (SAB) to support the scientific, pre-clinical and clinical development of its proprietary superior diabetes products to better improve the quality of…
Dr Sam Fazeli joins Arecor as Non-Executive Director
Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, is pleased to announce the appointment of Dr Sam Fazeli as Non-Executive Director of the Company.
Arecor team cycles for charity to celebrate its 10th anniversary
Arecor Ltd is celebrating its 10th year and to mark the occasion it is holding a 40Km and 80Km charity cycle ride, raising funds and awareness for the JDRF organisation.
Arecor awarded £1.05M from Innovate UK to support the advancement of its diabetes glucagon
Arecor's prototype liquid glucagon product shows stability and commercial viability; partnership with Innovate UK aims to accelerate pre-clinical asset towards proof-of-concept and first-in-human trials.
Arecor partners with JDRF to develop novel diabetes treatment
JDRF announces partnership with Arecor Ltd to support development of a stable, rapid-acting, ultra-concentrated insulin.
Arecor awarded Innovate UK proof of concept SMART Grant
Arecor Limited, which provides advanced formulation technology to the pharmaceutical industry, have been awarded a SMART award from Innovate UK, the UK’s innovation agency, to develop and demonstrate an ultra-long acting basal insulin to combat the risk of nocturnal hypoglycaemia in diabetic patients, improving patient safety and compliance.